Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.38 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.38 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583983 | 0.87 | NPC1 (0.47) | ATAD2SMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL4604677 | 0.86 | SMN1; SMN2 (0.41) | ATAD2SMN1; SMN2NPC1ALDH1A1ABCC9 | |
| SCHEMBL4603388 | 0.85 | SMN1; SMN2 (0.47) | ATAD2SMN1; SMN2ALDH1A1ABCC9ABCC8 | |
| SCHEMBL4604673 | 0.80 | MEN1 (0.45) | SMN1; SMN2NPC1MAPTALDH1A1KMT2A | |
| SCHEMBL8410461 | 0.77 | ATAD2 (0.60) | ATAD2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL584093 | 0.75 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1ABCC9ABCC8KCNJ11 | |
| SCHEMBL5345851 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2CCR3 | |
| SCHEMBL583651 | 0.72 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1ABCC9ABCC8KCNJ11 | |
| SCHEMBL27086299 | 0.72 | ATAD2 (0.45) | ATAD2SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL29920221 | 0.72 | ATAD2 (0.45) | ATAD2SMN1; SMN2NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
| US-20060069128-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | DUNCIA JOHN V | 2006-03-30 | — | — | US | disclosed |
| US-6992091-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1545524-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082616-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004024682-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | ATAD2 3930/4885SMN1; SMN2 4305/4885NPC1 848/4885 |
| US-20060069128-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | ACKR3, CCL11, CCR2 | ATAD2 2598/4885SMN1; SMN2 4237/4885NPC1 762/4885 |
| US-20040082616-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | ACKR3, CCL11, CCR2 | ATAD2 2598/4885SMN1; SMN2 4237/4885NPC1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.